Intermittent Fasting Shows Early Promise Against Huntington’s Disease in First Human Trial

A simple change in when people eat—not what they eat—may hold unexpected promise for one of the most devastating neurodegenerative diseases known to medicine. In the first clinical trial of its kind, researchers at Oregon Health & Science University tested whether time-restricted eating, a form of intermittent fasting that confines all daily food intake to a fixed eight-hour window, could benefit people in the early stages of Huntington’s disease. The results, published in Nature Metabolism, suggest that the dietary approach is feasible, well tolerated, and associated with favorable shifts in both clinical measures of the disease and a blood biomarker of nerve cell damage. While the study is small and uncontrolled, its findings open a tantalizing new front in the search for interventions that might slow a disease that has, until now, relentlessly outpaced every drug developed against it.

Huntington’s disease is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene, which produces a toxic mutant protein that progressively destroys neurons, particularly in the striatum and cortex. Symptoms typically emerge in midlife and include involuntary choreiform movements, cognitive decline, psychiatric disturbance, and profound metabolic abnormalities. Patients commonly experience unintended weight loss, altered glucose metabolism, mitochondrial dysfunction, and disrupted circadian rhythms—features that worsen as the disease advances and that strongly predict clinical progression. Body weight, in fact, is a robust predictor of how quickly the disease moves, and metabolic disturbances have been documented in the muscle, fibroblasts, and brains of affected individuals for decades. Despite an intense global research effort, including recent phase 3 trials of pridopidine and the antisense oligonucleotide tominersen, no therapy has yet been shown to decisively alter the disease course.

It is precisely this metabolic signature that made time-restricted eating an attractive candidate. In preclinical work, dietary restriction and intermittent fasting normalized glucose metabolism, elevated brain-derived neurotrophic factor, slowed disease progression, and extended survival in mutant huntingtin mice. Time-restricted feeding improved circadian dysfunction and motor symptoms in the Q175 mouse model, and circadian-based treatment strategies proved effective in the BACHD mouse model. Mechanistically, researchers believe the benefits stem from intermittent metabolic switching: the periodic transition from glucose-based fuel to ketone bodies and fatty acid oxidation that occurs during fasting windows. This metabolic switch triggers a cascade of adaptive responses, including enhanced autophagy—the cellular housekeeping process that clears damaged proteins, including mutant huntingtin aggregates—alongside improved mitochondrial function, reduced inflammation, and changes in circulating factors such as growth hormone, ghrelin signaling modulators like LEAP2, FGF21, and bile acids. The gut microbiota may also mediate some of the cognitive benefits observed with intermittent fasting in animal studies.

The new trial, registered as NCT06490367, enrolled 20 individuals with early-stage manifest Huntington’s disease in a 12-week open-label pilot study. Participants were asked to consume all of their daily calories within an eight-hour window, alongside standard-of-care diet and activity recommendations. The design deliberately avoided calorie counting or prescribed diets, isolating the timing of eating as the sole variable. Adherence was tracked through self-reported daily eating intervals and corroborated with time-stamped smartphone application data, which showed strong agreement between the two measures. Participants successfully compressed their eating windows from baseline habits, shifting the timing of both first and last caloric intake without substantially altering sleep onset or wake times—a critical point, since the intervention appeared to act on meal timing rather than simply disrupting sleep patterns.

The results were encouraging on multiple fronts. First, the intervention proved feasible: participants sustained the eight-hour eating window across the trial period with adherence rates indicating that most days met the protocol definition. Second, the regimen was well tolerated, an important consideration in a population at risk of weight loss, where aggressive caloric restriction could be harmful. Notably, the trial paired time-restricted eating with standard nutritional guidance precisely to guard against unintended weight decline. Third, and most strikingly, the researchers observed favorable changes in clinical measures of Huntington’s disease, including components of the composite Unified Huntington’s Disease Rating Scale, a validated outcome measure designed to capture clinically meaningful change in early-stage patients. In a disease defined by steady deterioration, even short-term stability or improvement on such measures in a small uncontrolled trial is noteworthy, though the authors and outside experts alike caution that practice effects and the absence of a control group make it impossible to attribute the changes confidently to the intervention.

Perhaps the most provocative finding concerned plasma neurofilament light chain, a protein released when neurons are injured that has emerged as one of the most reliable fluid biomarkers of neurodegeneration. Five-year longitudinal analyses have shown that plasma neurofilament light tracks neurodegeneration across the Huntington’s disease spectrum, and it is increasingly used as a secondary endpoint in therapeutic trials. In this pilot, levels of the biomarker moved in a favorable direction over the 12-week intervention, hinting—tentatively—that time-restricted eating might influence the very process of neuronal injury. The researchers also examined peripheral mitochondrial bioenergetics by measuring oxygen consumption rates in peripheral blood mononuclear cells using a mitochondrial stress test protocol, assessing basal respiration, ATP-linked respiration, maximal respiration, and spare respiratory capacity before and after the intervention. Given the well-documented mitochondrial dysfunction in Huntington’s disease, including transcriptional repression of PGC-1α by mutant huntingtin, these cellular energy measurements provide a mechanistic window into how a dietary intervention might interact with the disease’s underlying bioenergetic deficits.

The trial also monitored a broad panel of secondary outcomes reflecting the metabolic and inflammatory dimensions of the disease. Researchers assessed body composition, sleep quality using the Pittsburgh Sleep Quality Index, cognition with the Montreal Cognitive Assessment, and dietary quality using tools including the dietary inflammatory index and a Mediterranean diet score—an important control, since pro-inflammatory dietary patterns have been linked to dementia incidence in population studies. This comprehensive phenotyping reflects a deliberate strategy: rather than betting on a single endpoint, the pilot was designed to map the full physiological footprint of time-restricted eating in this population, generating hypotheses and effect-size estimates to power larger controlled trials. All source data from the study have been made publicly available through a Mendeley Data repository, and the trial protocol itself was published in advance in PLoS ONE, exemplifying the transparent, staged approach increasingly favored for lifestyle intervention research.

Experts in the field emphasize both the promise and the limitations of the work. As an open-label study without a placebo group, the trial cannot exclude expectation effects, regression to the mean, or practice effects on repeated neuropsychological testing, phenomena that are well documented in Huntington’s disease cohorts and even proposed as dynamic biomarkers of early cognitive change. The sample of 20 participants, while adequate for establishing feasibility, is far too small to detect the modest treatment effects that have frustrated large pharmaceutical trials. The history of Huntington’s disease research is littered with interventions that looked promising in early-phase studies—often with biomarker signals similar to those reported here—only to fail in definitive testing. Modeling work drawing on the Enroll-HD and GENERATION HD1 cohorts has highlighted how difficult it is to distinguish true disease modification from placebo response and natural variability in progression rates.

Nevertheless, the study represents a genuine milestone: the first time a fasting-based intervention has been formally tested in people with Huntington’s disease, translating nearly two decades of preclinical evidence into the clinic. If larger randomized controlled trials confirm that simply restricting the daily eating window can stabilize clinical measures and favorably shift neurodegeneration biomarkers, the implications would extend far beyond this single rare disease. Time-restricted eating is inexpensive, scalable, and already practiced by millions worldwide for weight management and metabolic health. A rigorous demonstration of neuroprotective effects would position meal timing as a genuine therapeutic modality for the brain. For now, the researchers urge restraint: the findings support the need for further investigation, not immediate clinical recommendations. But for a community that has endured decades of therapeutic disappointment, the idea that the clock, as much as the kitchen, might shape the course of Huntington’s disease is a source of hard-won and carefully qualified hope.

Subject of Research: Time-restricted eating as a lifestyle intervention in early-stage Huntington's disease

Article Title: Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study

Article References: Wells, R. G., Neilson, L. E., McHill, A. W., Gray, N. E., Quinn, J. F., & Hiller, A. L. (2026). Effects of time-restricted eating in early-stage Huntington’s disease: a pilot study. Nature Metabolism. https://doi.org/10.1038/s42255-026-01612-x

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01612-x

Keywords: Huntington's disease, time-restricted eating, intermittent fasting, neurodegeneration, neurofilament light, mitochondrial dysfunction, circadian rhythms, autophagy, pilot trial, metabolism, biomarkers, lifestyle intervention